Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
If the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch Read More »
